Tags

Type your tag names separated by a space and hit enter

Elevated risk of prostate cancer among men with Lynch syndrome.
J Clin Oncol 2013; 31(14):1713-8JC

Abstract

PURPOSE

Prostate cancer has been described as a component tumor of Lynch syndrome (LS), with tumors obtained from mutation carriers demonstrating the DNA mismatch repair deficiency phenotype. Previous studies quantifying prostate cancer risk in LS have provided conflicting results.

METHODS

We examined cancer histories of probands and their first- through fourth-degree relatives for 198 independent mutation-positive LS families enrolled in two US familial cancer registries. Modified segregation analysis was used to calculate age-specific cumulative risk or penetrance estimates, with accompanying Wald-type CIs. Cumulative lifetime risks and hazard ratio (HR) estimates for prostate cancer were calculated and compared with those of the general population.

RESULTS

Ninety-seven cases of prostate cancer were observed in 4,127 men. Median age at prostate cancer diagnosis was 65 years (range, 38 to 89 years), with 11.53% of affected individuals diagnosed before age 50 years. The cumulative risk of prostate cancer at ages 60 and 80 years was 6.30% (95% CI, 2.47 to 9.96) and 30.0% (95% CI, 16.54 to 41.30), as compared with the population risk of 2.59% and 17.84%, respectively. The overall prostate cancer HR among carriers was 1.99 (95% CI, 1.31 to 3.03).

CONCLUSION

The cumulative lifetime risk of prostate cancer in individuals with LS is two-fold higher than in the general population and is slightly higher in carriers diagnosed before age 60 years (HR, 2.48; 95% CI, 1.34 to 4.59). These estimates are clinically valuable to quantify risk for both patients and providers.

Authors+Show Affiliations

University of Michigan, 300 North Ingalls, Ann Arbor, MI 48109-5419, USA. vraymond@umich.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23530095

Citation

Raymond, Victoria M., et al. "Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 31, no. 14, 2013, pp. 1713-8.
Raymond VM, Mukherjee B, Wang F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. 2013;31(14):1713-8.
Raymond, V. M., Mukherjee, B., Wang, F., Huang, S. C., Stoffel, E. M., Kastrinos, F., ... Gruber, S. B. (2013). Elevated risk of prostate cancer among men with Lynch syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31(14), pp. 1713-8. doi:10.1200/JCO.2012.44.1238.
Raymond VM, et al. Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. J Clin Oncol. 2013 May 10;31(14):1713-8. PubMed PMID: 23530095.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Elevated risk of prostate cancer among men with Lynch syndrome. AU - Raymond,Victoria M, AU - Mukherjee,Bhramar, AU - Wang,Fei, AU - Huang,Shu-Chen, AU - Stoffel,Elena M, AU - Kastrinos,Fay, AU - Syngal,Sapna, AU - Cooney,Kathleen A, AU - Gruber,Stephen B, Y1 - 2013/03/25/ PY - 2013/3/27/entrez PY - 2013/3/27/pubmed PY - 2013/7/3/medline SP - 1713 EP - 8 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 31 IS - 14 N2 - PURPOSE: Prostate cancer has been described as a component tumor of Lynch syndrome (LS), with tumors obtained from mutation carriers demonstrating the DNA mismatch repair deficiency phenotype. Previous studies quantifying prostate cancer risk in LS have provided conflicting results. METHODS: We examined cancer histories of probands and their first- through fourth-degree relatives for 198 independent mutation-positive LS families enrolled in two US familial cancer registries. Modified segregation analysis was used to calculate age-specific cumulative risk or penetrance estimates, with accompanying Wald-type CIs. Cumulative lifetime risks and hazard ratio (HR) estimates for prostate cancer were calculated and compared with those of the general population. RESULTS: Ninety-seven cases of prostate cancer were observed in 4,127 men. Median age at prostate cancer diagnosis was 65 years (range, 38 to 89 years), with 11.53% of affected individuals diagnosed before age 50 years. The cumulative risk of prostate cancer at ages 60 and 80 years was 6.30% (95% CI, 2.47 to 9.96) and 30.0% (95% CI, 16.54 to 41.30), as compared with the population risk of 2.59% and 17.84%, respectively. The overall prostate cancer HR among carriers was 1.99 (95% CI, 1.31 to 3.03). CONCLUSION: The cumulative lifetime risk of prostate cancer in individuals with LS is two-fold higher than in the general population and is slightly higher in carriers diagnosed before age 60 years (HR, 2.48; 95% CI, 1.34 to 4.59). These estimates are clinically valuable to quantify risk for both patients and providers. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/23530095/full_citation L2 - http://ascopubs.org/doi/full/10.1200/JCO.2012.44.1238?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -